


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C09B 23/02, C07H 21/00, 19/04, C12Q 1/68	A1	(11) International Publication Number: WO 99/37717 (43) International Publication Date: 29 July 1999 (29.07.99)
(21) International Application Number: PCT/US99/01163		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 19 January 1999 (19.01.99)		
(30) Priority Data: 09/012,525 23 January 1998 (23.01.98) US		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant: THE PERKIN-ELMER CORPORATION [US/US]; 850 Lincoln Centre Drive, Foster City, CA 94404 (US).		
(72) Inventors: LEE, Linda, G.; 3187 Stelling Drive, Palo Alto, CA 94303 (US). GRAHAM, Ronald, J.; 3610 Andrews Drive #315, Pleasanton, CA 94588 (US). MULLAH, Khairuzzaman, B.; 32804 Regents Boulevard, Union City, CA 94404 (US). HAXO, Francis, T.; 946 Page Street, San Francisco, CA 94117 (US).		
(74) Agent: GROSSMAN, Paul, D.; The Perkin-Elmer Corporation, 850 Lincoln Centre Drive, Foster City, CA 94404 (US).		

(54) Title: ASYMMETRIC CYANINE DYE QUENCHERS



(57) Abstract

The invention provides an asymmetric cyanine dye compound having structure (1) including substituted forms thereof, wherein, at least one of R₁ and R₂ is linking group, X is O, S, or Se, and n ranges from 0 to 2. The invention further provides reporter-quencher dye pairs comprising the asymmetric cyanine dyes, dye-labeled polynucleotides incorporating the asymmetric cyanine dyes, and hybridization detection methods utilizing the dye-labeled polynucleotides.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ASYMMETRIC CYANINE DYE QUENCHERS

5

FIELD OF THE INVENTION

This invention relates to dye compounds useful as quenchers in a reporter-quencher energy-transfer dye pair. More specifically, this invention relates to cyanine quencher compounds, reagents incorporating such compounds and methods utilizing
10 such compounds and/or reagents.

BACKGROUND

Nucleic acid hybridization assays comprise an important class of techniques in
15 modern biology. Such assays have diverse applications including the diagnosis of inherited disease, human identification, identification of microorganisms, paternity testing, virology, and DNA sequencing, i.e., sequencing by hybridization.

An important aspect of nucleic acid hybridization assays is the method used to
20 facilitate detection of the hybridization event. A particularly important class of methods used in nucleic acid hybridization assays employs a reporter-quencher energy-transfer dye pair comprising a "reporter" dye and a "quencher" dye which interact through a fluorescence resonance energy transfer (FRET) process. In these methods, the reporter is a luminescent compound that can be excited either by chemical reaction, producing
25 chemiluminescence, or by light absorption, producing fluorescence. The quencher can interact with the reporter to alter its light emission, usually resulting in the decreased emission efficiency of the reporter. This phenomenon is called quenching. The efficiency of quenching is a strong function of the distance between the reporter molecule and the quencher molecule. Thus, in a nucleic acid hybridization assay,
30 detection of a hybridization event is accomplished by designing an energy transfer system in which the spacing between a reporter and a quencher is modulated as a result of the hybridization.


Quenchers which are presently used in FRET-based nucleic acid hybridization assays are themselves fluorescent. That is, in addition to quenching the fluorescence of the reporter, the quencher produces fluorescent emissions. This is problematic, 5 particularly in assays employing multiple spectrally-resolvable reporters, because the quencher fluorescence can interfere with the fluorescent signal produced by one or more of the reporters.

Thus, there remains a continuing need for quencher dyes which are themselves 10 substantially non-fluorescent.

SUMMARY

The present invention is directed towards our discovery of a class of non-fluorescent cyanine quencher compounds which are useful in the context of a reporter-quencher energy-transfer dye pair. These quencher compounds find particular application in nucleic acid hybridization assays employing fluorescence energy transfer as a means of detection. 15

20 In a first aspect, the invention comprises an asymmetric cyanine dye compound having the structure



including substituted forms thereof, wherein at least one of R₁ and R₂ is linking group, X is O, S, or Se, and n ranges from 0 to 2.

25 In a second aspect, the invention includes a reporter-quencher energy-transfer dye pair comprising a reporter dye and a quencher dye, wherein the quencher dye is an asymmetric cyanine dye compound of the first aspect.

In a third aspect, the invention includes a an oligonucleotide having a cyanine dye quencher according to the first aspect covalently attached thereto.

In a fourth aspect, the invention provides a method for detecting a target nucleic acid sequence including the steps of providing a sample nucleic acid including at least one target nucleic acid sequence, and hybridizing a labeled oligonucleotide probe to the target nucleic acid sequence, the labeled oligonucleotide probe being labeled with an asymmetric cyanine dye compound of the first aspect. In a particularly preferred embodiment of this fourth aspect, the method further includes the step of digesting the oligonucleotide probe such that one or both of the reporter and quencher dyes is removed from the oligonucleotide probe.

Various aspects and embodiments of the above-described invention achieve one or more of the following important advantages over known quencher dye compounds. The asymmetric cyanine quenchers of the present invention may be easily covalently linked to a reagent, e.g., a polynucleotide. Furthermore, oligonucleotide probes labeled with the asymmetric cyanine quenchers of the present invention exhibit enhanced hybridization stability as compared to conventionally labeled probes, thereby allowing for the use of shorter probes which are more sensitive to hybridization mismatches. In addition, the asymmetric cyanine quenchers of the present invention are essentially non-fluorescent, thereby providing additional spectrum which can be occupied by one or more additional reporters.

These and other objects, features, and advantages of the present invention will become better understood with reference to the following description, drawings, and appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B show several preferred cyanine dye compounds of the present invention.

FIGS. 2A and 2B show a generalized synthetic scheme for the synthesis of the cyanine dye quenchers of the present invention.

5 FIGS. 3A-3D show a synthetic scheme for the synthesis a first preferred cyanine dye quencher of the present invention.

FIGS. 4A and 4B show a synthetic scheme for the synthesis a second preferred cyanine dye quencher of the present invention.

10 FIGS. 5A-5E shows a schematic depiction of several hybridization detection methods according to the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

15 Reference will now be made in detail to the preferred embodiments of the invention, examples of which are illustrated in the accompanying drawings. While the invention will be described in conjunction with the preferred embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On 20 the contrary, the invention is intended to cover alternatives, modifications, and equivalents, which may be included within the invention as defined by the appended claims.

I. DEFINITIONS

25 Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings:

“Energy transfer” and “fluorescence quenching” refer to a processes whereby energy is removed from an electronically excited luminescent 30 “reporter” molecule by a “quencher” molecule, thereby returning the reporter molecule to its ground state without the emission of light from the reporter molecule. The reporter molecule may be excited to one of its higher energy levels by any of a number of process, including light absorption and chemical reaction.

"Spectral resolution" in reference to a set of dyes means that the fluorescent emission bands of the dyes are sufficiently distinct, i.e., sufficiently non-overlapping, that reagents to which the respective dyes are attached, e.g. polynucleotides, can be
5 distinguished on the basis of a fluorescent signal generated by the respective dyes using standard photodetection systems, e.g. employing a system of band pass filters and photomultiplier tubes, charged-coupled devices and spectrographs, or the like, as exemplified by the systems described in U.S. Pat. Nos. 4,230,558, 4,811,218, or in Wheless et al, pgs. 21-76, in *Flow Cytometry: Instrumentation and Data Analysis*
10 (Academic Press, New York, 1985).

"Linking group" means a moiety capable of reacting with a "complementary functionality" attached to a reagent, such reaction forming a "linkage" connecting a dye to a reagent. Preferred linking groups include isothiocyanate, sulfonyl chloride, 4,6-dichlorotriazinyl, carboxylate, succinimidyl ester, or other active carboxylate whenever the complementary functionality is amine. Alternatively, the linking group may be amine. Preferably the linking group is maleimide, halo acetyl, or iodoacetamide whenever the complementary functionality is sulphhydryl. See R. Haugland, *Molecular Probes Handbook of Fluorescent Probes and Research Chemicals*, Molecular probes, Inc. (1992).
15 In a particularly preferred embodiment, the linking group is a N-hydroxysuccinimidyl (NHS) ester and the complementary functionality is an amine, where to form the NHS ester, a dye of the invention including a carboxylate linking group is reacted with dicyclohexylcarbodiimide and N-hydroxysuccinimide.
20

25 "Lower alkyl" denotes straight-chain and branched hydrocarbon moieties containing from 1 to 8 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, sec-butyl, neopentyl, tert-pentyl, and the like.

30 "Nucleoside" refers to a compound consisting of a purine, deazapurine, or pyrimidine nucleoside base, e.g., adenine, guanine, cytosine, uracil, thymine, deazaadenine, deazaguanosine, and the like, linked to a pentose at the 1' position. When the nucleoside base is purine or 7-deazapurine, the sugar moiety is attached at the 9-position of the purine or deazapurine, and when the nucleoside base is pyrimidine, the

sugar moiety is attached at the 1-position of the pyrimidine, e.g., Kornberg and Baker, *DNA Replication*, 2nd Ed. (Freeman, San Francisco, 1992). The term "nucleotide" as used herein refers to a phosphate ester of a nucleoside, e.g., triphosphate esters, wherein
5 the most common site of esterification is the hydroxyl group attached to the C-5 position of the pentose. The term "nucleoside/tide" as used herein refers to a set of compounds including both nucleosides and nucleotides. "Analogs" in reference to nucleosides/tides include synthetic analogs having modified base moieties, modified sugar moieties and/or modified phosphate moieties, e.g. described generally by Scheit, *Nucleotide Analogs* (John
10 Wiley, New York, 1980). Phosphate analogs comprise analogs of phosphate wherein the phosphorous atom is in the +5 oxidation state and one or more of the oxygen atoms is replaced with a non-oxygen moiety. Exemplary phosphate analogs include but are not limited to phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranimidate, phosphoramidate,
15 boronophosphates, including associated counterions, e.g., H⁺, NH₄⁺, Na⁺, if such counterions are present. Exemplary base analogs include but are not limited to 2,6-diaminopurine, hypoxanthine, pseudouridine, C-5-propyne, isocytosine, isoguanine, 2-thiopyrimidine, and other like analogs. Exemplary sugar analogs include but are not limited to 2'- or 3'-modifications where the 2'- or 3'-position is hydrogen, hydroxy,
20 alkoxy, e.g., methoxy, ethoxy, allyloxy, isopropoxy, butoxy, isobutoxy and phenoxy, amino or alkylamino, fluoro, chloro and bromo. The term "labeled nucleoside/tide" refers to nucleosides/tides which are covalently attached to a label.

"Polynucleotide" or "oligonucleotide" means polymers of natural nucleotide monomers or analogs thereof, including double and single stranded deoxyribonucleotides, ribonucleotides, α -anomeric forms thereof, and the like. Usually the nucleoside monomers are linked by phosphodiester linkages, where as used herein, the term "phosphodiester linkage" refers to phosphodiester bonds or bonds including phosphate analogs thereof, including associated counterions, e.g., H⁺, NH₄⁺, Na⁺, if such counterions are present. Polynucleotides typically range in size from a few monomeric units, e.g. 5-40, to several thousands of monomeric units. Whenever a polynucleotide is represented by a sequence of letters, such as "ATGCCTG," it will be understood that the nucleotides are in 5'->3' order from left to right and that "A" denotes deoxyadenosine, "C" denotes

deoxycytidine, "G" denotes deoxyguanosine, and "T" denotes deoxythymidine, unless otherwise noted.

5 "Substituted" as used herein refers to a molecule wherein one or more hydrogen atoms are replaced with one or more non-hydrogen atoms, functional groups or moieties. For example, an unsubstituted nitrogen is —NH₂, while a substituted nitrogen is —NHCH₃. Exemplary substituents include but are not limited to halo, e.g., fluorine and chlorine, lower alkyl, lower alkene, lower alkyne, sulfate, sulfonate, sulfone, amino, 10 ammonium, amido, nitrile, lower alkoxy, phenoxy, aromatic, phenyl, polycyclic aromatic, electron-rich heterocycle, and linking group.


"Methine bridge" or "polymethine bridge" refers to a portion of a cyanine dye compound connecting two base portions, the bridge having the following structure

15 $\text{---}(\text{CH}=\text{CH})_n\text{---CH---}$,


where n typically ranges from 0 to 2.

"Xanthene dyes" are dyes which comprise the following fused three-ring structure


20




where R is oxygen (fluorescein) or —NH (rhodamines), including substituted forms thereof. Exemplary substituted fluorescein compounds include the "NED" dye which has the structure




the "TET" dye which has the structure




and the "FAM" dye which has the structure



An exemplary rhodamine dye is the "TAMRA" or "TMR" dye which has the structure




“Coumarin dyes” are dyes which comprise the following fused two-ring structure



5

where R is oxygen (hydroxycoumarin) or —NH (aminocoumarin), including substituted forms thereof.

“BODIPY™ dyes” are dyes comprising the following fused ring structure



10

including substituted forms thereof. See the *Handbook of Fluorescent Probes and Research Chemicals, Sixth Addition*, Haugland, Molecular Probes, Inc. (1996).

15


“Cyanine dyes” are dyes comprising two nitrogen-heterocyclic rings joined by a methine, or polymethine, bridge. An exhaustive review of such dyes is provided by Ficken (Ficken, *The Chemistry of Synthetic Dyes*, Vol IV, Venkataraman (1971)).

I. ASYMMETRIC CYANINE DYE COMPOUNDS

20

A. Structure

In a first aspect, the present invention comprises a novel class of cyanine dye compounds useful as non-fluorescent quenchers. These compounds have the general structure shown in Formula I immediately below, including substituted forms thereof, 5 where at least one of R₁ and R₂ is linking group, X is O, S, or Se, and n ranges from 0 to 2. (Note that all molecular structures provided herein are intended to encompass not only the exact electronic structures presented, but also include all resonant structures, protonation states and associated counterions thereof.)



10

FORMULA 1

Preferably, when the compound is to be used as a non-fluorescent quencher, the compound includes a nitro C-3 substituent. For example, compounds 5, 9, 20, 21 and 15 23.

In an alternative preferred embodiment, the linking group of the compound of Formula 1 is a lower alkylamine or a lower alkylcarboxy moiety, where a particularly preferred lower alkylcarboxy is $-(\text{CH}_2)_n\text{N}^+(\text{CH}_3)_2(\text{CH}_2)_n\text{CO}_2\text{H}$, where n ranges from 2 to 12. For example, compound 23.

In another preferred embodiment, one of R₁ or R₂ is $-(\text{CH}_2)_n\text{N}^+(\text{CH}_3)_3$, where n ranges from 2 to 12, and the other of R₁ or R₂ is linking group.

25 In yet another preferred embodiment, the X-group in the cyanine compounds of the invention is sulfur. For example, compounds 5, 9, 20, 21, 22 and 23.

In another preferred embodiment, the compound of Formula 1 includes a fused aromatic, or substituted aromatic, substituent bonded at positions 1 and 2, positions 2

30

and 3; and/or positions 3 and 4. More preferably, the substituted aromatic includes one or more nitro substituents. For example, compounds 21 and 22.

5 In an additional preferred embodiment of the present invention, the compound of Formula 1 includes a bridging group that when taken together with R₂ and the proximate carbon of the methine bridge forms a ring structure having 5 to 7 members, more preferably 6 members. For example, compounds 20 and 21.

10 **B. Synthesis**

Generally, the non-fluorescent cyanine dye quenchers may be prepared as follows. See FIGS. 2A and 2B. A quaternized benzazole derivative, e.g. a benzothiazolium salt 10 or 13, is mixed with a lepidinium salt, 11, and refluxed under basic conditions, e.g. diisopropylethylamine in methanol, or pyridine. The solvent is evaporated and the crude solid is washed with dilute hydrochloric acid , e.g., 5% in water, and dried.

20 The dyes may be rendered amino-reactive by converting a carboxylic acid group to a succinimidyl ester. For example, dye 12 or 14 is dissolved in DMF with succinimidyl tetramethyluronium salt and DIPEA. The product is precipitated by the addition of dilute HCl, washed and dried.

II. DYE PAIRS INCLUDING NON-FLUORESCENT CYANINE DYES

25 Reporter-quencher dye pairs may be composed of any pair of molecules which can participate in an energy transfer process. Exemplary reporters may be selected from xanthene dyes, including fluoresceins, and rhodamine dyes. Many suitable forms of these compounds are commercially available with various substituents on their xanthene rings which can be used as the site for bonding or as the bonding functionality for 30 attachment to an oligonucleotide. Another group of fluorescent compounds are the naphthylamines, having an amino group in the alpha or beta position. Included among such naphthylamino compounds are 1-dimethylaminonaphthyl-5-sulfonate, 1-anilino-8-naphthalene sulfonate and 2-p-tuidinyl-6-naphthalene sulfonate. Other dyes include

but are not limited to 3-phenyl-7-isocyanatocoumarin, acridines, such as 9-isothiocyanatoacridine and acridine orange, N-(p-(2-benzoxazolyl)phenyl)maleimide, benzoxadiazoles, stilbenes, pyrenes, and the like.

5

Preferably, reporter molecules are selected from fluorescein and rhodamine dyes. These dyes and appropriate linking methodologies for attachment to oligonucleotides are described elsewhere (Khanna et al (cited above); Marshall, *Histochemical J.*, 7: 299-303 (1975); Mechnen et al, U.S. patent 5,188,934; Menchen et al, European Patent Application No. 87310256.0; and Bergot et al, International Application PCT/US90/05565). Particularly preferred reporter molecules include fluorescein dyes NED, TET and FAM.

Exemplary reporter-quencher pairs include the following:

Reporter	Quencher
FAM	Nitrothiazole Orange (Compound 9)
FAM	Nitrothiazole Blue (Compound 5)
TET	Nitrothiazole Blue (Compound 5)
TET	Nitrothiazole Blue (Compound 5)
NED	Nitrothiazole Blue (Compound 5)

15

III. DYE-LABELED POLYNUCLEOTIDES

In another aspect, the present invention comprises polynucleotides labeled with the non-fluorescent cyanine dyes of the invention. Such labeled polynucleotides are useful in a number of important contexts including as oligonucleotide hybridization probes and oligonucleotide ligation probes.

Singly- or doubly-labeled polynucleotides may be prepared using any of a number of well known methods. Methods suitable for labeling an oligonucleotide at the 3'end include but are by no means limited to (1) periodate oxidation of a 3'-terminal

ribonucleotide, followed by reaction with an amine-containing label (Heller and Morrison, In *Rapid Detection and Identification of Infectious Agents* (D.T. Kingsbury and S. Falkow, eds.), pp 245-256, Academic Press (1985)); (2) enzymatic addition of a 3'-aliphatic amine-containing nucleotide using deoxynucleotidyl transferase, followed by reaction with an amine-reactive label (Morrison, European Patent Application No. 232 967); and (3) periodate oxidation of a 3'-ribonucleotide, followed by reaction with 1,6-hexanediamine to provide a 3'-terminal aliphatic amine, followed by reaction with an amine-reactive label (Cardullo et al., *Proc. Natl. Acad. Sci. USA*, 85: 8790-8794 (1988)).

10

Methods for labeling the 5' end of an oligonucleotide include (1) periodate oxidation of a 5'-to-5'-coupled ribonucleotide, followed by reaction with an amine-reactive label (Heller and Morrison, 1985); (2) condensation of ethylenediamine with 5'-phosphorylated polynucleotide, followed by reaction with an amine reactive label (Morrison, 1987); and (3) introduction of an aliphatic amine substituent using an aminoethyl phosphite reagent in solid-phase DNA synthesis, followed by reaction with an amine reactive label (Cardullo, 1988).

In addition to these end-labeling methods, labels can be placed at specific locations within synthetic polynucleotides using amine-containing nucleotide phosphoramidite reagents, e.g., 5'-dimethoxytrityl-5-[N-trifluoroacetylaminohexy]-3-acrylimido]-2-deoxyuridine, 3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, e.g., Amino-Modifier C6 dT phosphoramidite (Linker Arm Nucleotide, Glen Research, Inc.) (Mathies et al., U.S. Patent No. 5,688,648).

25

For a thorough review of oligonucleotide labeling procedures see R. Haugland in *Excited States of Biopolymers*, Steiner ed., Plenum Press (1983), *Fluorogenic Probe Design and Synthesis: A Technical Guide*, PE Applied Biosystems (1996), and G. T. Herman, *Bioconjugate Techniques*, Academic Press (1996).

30

Generally, the design of oligonucleotide hybridization probes including the non-fluorescent cyanine dye quenchers of the invention follows conventional teachings. Thus, in designing labeled oligonucleotide hybridization probes, the following general

guidelines should be followed: (1) if the target nucleic acid sequence is located within a PCR amplicon, the probe sequence should be such that the probe hybridizes at a location on the sequence between the PCR primers; (2) probes should be about 20-30
5 nucleotides long so as to ensure good hybridization kinetics and specificity of binding;
(3) avoid secondary structure in the probe and target nucleic acid sequence; (4) if the probe is being used in combination with a pair of PCR primers, the probe should not hybridize to either of the forward and reverse primers; and (5) avoid probes with long stretches of a single nucleotide, i.e., more than four; and (6) when choosing between a
10 probe sequence and its complement, pick the strand that has more C nucleotides than G nucleotides.

IV. HYBRIDIZATION METHODS UTILIZING NON-FLUORESCENT CYANINE DYES

15

Several hybridization assay formats that employ energy transfer as a means for detecting hybridization have been described, five of which are discussed below and shown schematically in FIGS. 5A-E.

20

In a first assay format, shown in FIG. 5A, the sequences of two oligonucleotide probes are selected such that they will hybridize to contiguous regions of a target nucleic acid 5. The first probe 10, hybridizing toward the 5'-terminus of the target nucleic acid, is labeled near its 5'-terminus with a reporter label, whereas the second probe 15 is labeled near its 3'-terminus with a quencher label. Thus, when a 3-way
25 hybrid 20 is formed among the target nucleic acid 5 and the first 10 and second 15 probes, the reporter and quencher are brought into close proximity and energy transfer can take place. Thus, in this format, the emission of the reporter is quenched upon the hybridization of the two probes to the target. (Heller et al., European Patent Application No. 070 685 (1983))

30

In a second assay format, shown in FIG. 5B, two oligonucleotide probes 25 and 30 which are complementary to each other and which each contain a reporter or a quencher label are used. The location of the labels is selected such that when the probes

are hybridized to one another to form a probe-probe hybrid 35, the quenching interaction is favored, whereas an insignificant amount of quenching occurs when the probes are separated. The detection of target nucleic acid is achieved by denaturing 5 both the target nucleic acid 5 and the probes 25 and 30, and then allowing the strands to reanneal. Thus, there is a competition between probe-probe hybridization and probe-target hybridization. The more target nucleic acid that is present, the larger the number 10 of probes that will hybridize to the target forming probe-target hybrids 40. The presence of target DNA is indicated by an increased emission from the reporter R due to the reduced quenching by the quencher Q caused by a reduction in the number of probe-probe hybrids. (Morrison, European Patent Application 232 967 (1987)).

A third assay format, depicted in FIG. 5C, uses only one labeled probe 45 and a dye that binds preferentially to double-stranded nucleic acid 50. This dye 50 may 15 intercalate between the base pairs of the double-stranded species or may bind to the outside of the helix and serves as a quencher. Thus, in the absence of hybridization, the quencher Q does not bind to the single-stranded probe 45, and the reporter R is unaffected by Q. However, in the presence of a target nucleic acid 5, the probe 45 20 hybridizes to the target nucleic acid and Q binds to the resulting double-stranded region forming a target-probe-dye complex 55. In the complex, Q and R are placed in close proximity and energy transfer or fluorescence quenching may take place. Thus, in this format, the emission of the reporter is quenched upon the hybridization of the probe to the target. (Heller and Morrison, In *Rapid Detection and Identification of Infectious Agents* (D.T. Kingsbury and S. Falkow, eds.), pp 245-256, Academic Press (1985)).

25

In a fourth assay format, shown in FIG. 5D, a single probe 60 is used which is labeled with both a reporter and a quencher. The location of the reporter and quencher labels is selected so that when the probe is in a single stranded state, i.e., unhybridized 30 to a target nucleic acid, the single-stranded conformation of the probe is such that the reporter and quencher labels are in close proximity thereby allowing energy transfer to take place. In one alternative method of achieving this single-stranded confirmation, the reporter and quencher are brought into close proximity by designing the probe sequence such that a hairpin forms at the ends of the probe thereby forcing the reporter and

quencher together (Bagwell, European patent Application No. 601 889 (1994); Tyagi and Kramer, *Nature Biotechnology*, 14: 303-308 (1996)). In another alternative method for achieving this single-stranded conformation, the reporter and quencher are located 5 far enough apart on the probe such that the random-coil confirmation of the single-stranded probe serves to bring the quencher and reporter into sufficiently close proximity (Mayrand, U.S. Patent No. 5,691,146). However, when the double-labeled probe 60 is hybridized to a target nucleic acid 5 forming a probe-target hybrid 65, the reporter and quencher are separated from one another, and the quenching interaction is 10 prevented. Thus, in this format, the emission of the reporter becomes unquenched upon the hybridization of the probe to the target.

In a fifth assay format, referred to herein as the "Taqman" assay and illustrated in FIG. 5E, a doubly-labeled probe including both a reporter label and a quencher label 15 is digested upon hybridization to a target nucleic acid thereby liberating one or both of the labels from the probe (Holland et al., *Proc. Natl. Acad. Sci. USA*, 88: 7276-7280 (1991); Livak, U.S. Patent No. 5,538,848). In this method the doubly-labeled probe 75 is hybridized to a target nucleic acid 5. In addition, an oligonucleotide primer 70 is hybridized to the target nucleic acid at a position upstream from the probe, i.e., closer to 20 the 3'-end of the target nucleic acid. The primer 70 is then extend using a polymerase enzyme thereby forming an extended primer 80, e.g., using a DNA polymerase. During the primer extension reaction, a 5'-3' nuclease activity of the polymerase serves to cut the probe 75 so as to form a first probe fragment 85 including the reporter label and a second probe fragment 90 including the quencher label. Thus, the reporter and 25 quencher labels are separated thereby preventing energy transfer between the two. Thus, in this format, the emission of the reporter becomes unquenched upon the hybridization of the probe to the target and subsequent digestion of the probe.

Note that in each of the five assay formats discussed above and depicted in 30 FIGS. 5A-E, unless otherwise specified, the location of the reporter and quencher is arbitrary. That is, while the reporter may be depicted on one probe and the quencher on another probe, their positions may be reversed.

While the assay formats described above are represented in terms of systems employing only a single reporter label, multi-reporter systems may also be practiced. Such multi-reporter systems are advantageous in applications requiring the analysis of 5 multiple hybridization events in a single reaction volume. In such systems, each of the reporter molecules produce emissions which are spectrally resolvable from the emissions from any of the other reporters. The particular quencher used with each reporter can be the same or different, depending on the spectral properties of the quencher and reporter.

10

Each of the assays described above may be conducted in combination with a nucleic acid amplification step, e.g., PCR. That is, prior to conducting the hybridization assay, all or part of the nucleic acid sample may be amplified. When performed in combination with an amplification step, the hybridization assay may be conducted in an 15 end-point mode or a real-time mode. In an end-point mode, the hybridization assay is performed after the amplification reaction is complete, e.g., after all or substantially all of the amplification cycles of a PCR reaction have been completed. In a real-time mode, a hybridization assay is performed multiple times during the amplification reaction, e.g., after each thermocycle of a PCR process (Higuchi, European Patent 20 Application No. 512 334). The real-time mode is preferred when a quantitative measure of the initial amount of target nucleic acid is required, e.g., the copy-number of pathogen nucleic acid present in a blood sample.

V. EXAMPLES

25 The invention will be further clarified by a consideration of the following examples, which are intended to be purely exemplary of the invention and not to in any way limit its scope.

EXAMPLE 1

30 **Synthesis of Nitrothiazole Blue 5 and Nitrothiazole Orange 9**

The syntheses of nitrothiazole blue 5 and nitrothiazole orange 9 are outlined in FIGS. 3 and 4.

Preparation of 6-nitrobenzothiazole 1.

See FIG. 3A. Nitration of 2-methylbenzothizole was performed following the method of Mizuno, *J. Pharm. Soc. Japan*, 72, 745 (1952). A mixture of fuming nitric acid (1.6 mL) and concentrated sulfuric acid (1.2 mL) was added to an ice-cooled solution of 2-methylbenzothiazole (2 g) in sulfuric acid (8 mL). The solution was allowed to warm to room temperature for one hour, then poured onto 100 mL of ice. The solid was filtered, washed with water, and recrystallized from ethanol (80 mL) to provide 2.5 g of yellowish needles.

10

Preparation of 3-methyl-6-nitrobenzothiazolium p-toluenesulfonate 2.

See FIG. 3A. A mixture of 6-nitrobenzothiazole (1 g) and methyl-p-toluenesulfonate (1.2 g) was heated to 140°C for 20 min. The solid was washed with acetone and filtered to provide a bluish solid (1.1 g).

15

Preparation of 2-(2'-acetanilidovinyl)-3-methylbenzothiazolium p-toluenesulfonate

3

See FIG. 3A. A mixture of 3-methyl-6-nitrobenzothiazolium p-toluenesulfonate 2 (200 mg, 0.52 mmol), diphenylformamidine (160 mg, 0.8 mmol) and acetic anhydride (2 mL) was refluxed for 20 min. The cooled solution was triturated with ether to provide a dark brown solid (200 mg).

Preparation of 1-(5'-carboxypentyl)-lepidinium bromide 4.

See FIG. 3B. A mixture of lepidine (5 g) and 6-bromohexanoic acid (10 g) was heated to 130 °C for 6 h. The solid was washed with acetone and filtered to provide an off-white solid (10.5 g).

Preparation of nitrothiazole blue 5.

See FIG. 3C. A mixture of the acetanilide 3 (65 mg, 0.13 mmol) and the lepidinium bromide 4 (66 mg, 0.2 mmol) and pyridine (1 mL) was combined and refluxed for 30 min. The blue solution was concentrated to dryness and washed with 5 X 1 mL 5% HCl. The residue was dried to provide a blue solid (67 mg).

Preparation of nitrothiazole blue succinimidyl ester.

To a solution of nitrothiazole blue 5 (31 mg, 0.056 mmol) in dimethylformamide (0.5 mL) and diisopropylethylamine (0.05 mL) was added *O*-(*N*-succinimidyl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (34 mg, 0.12 mmol). The mixture was warmed to 70 °C for 10 min. Reaction progress was monitored by TLC on silica gel using 600:60:16 dichloromethane:methanol:acetic acid as the eluant. To the homogeneous solution was added 5% HCl (2 mL). The precipitate was washed with additional HCl and dried to provide a dark solid (30 mg).

10

Preparation of 2-(methylthio)-6-nitrobenzothiazole 7.

See FIG. 4A. Fuming nitric acid (1.93 g) was added dropwise to a solution of 2-(methylthio)benzothiazole (5 g) in concentrated sulfuric acid (16.8 g) cooled in an ice bath. After stirring at 5 °C for 3 h the solution was poured onto ice and filtered to provide a yellow solid (5.7 g, 25 mmol, 91%).

15

Preparation of 3-methyl-2-(methylthio)-benzothiazolium p-toluenesulfonate 8.

A mixture of 6-nitro-2-(methylthio)benzothiazole 7 (0.5 g, 2.2 mmol) and methyl-*p*-toluenesulfonate (3.7 g, 20 mmol) was heated from 120°C to 145 °C over one hour. To the cooled solution was added 30 mL of ether. The resulting amorphous solid was triturated with acetone to provide a pale mauve solid (0.57 g, 1.4 mmol, 63%).

Preparation of nitrothiazole orange 9.

See FIG. 4B. To a solution of 3-methyl-2-(methylthio)-benzothiazolium *p*-toluenesulfonate 8 (50 mg, 0.12 mmol) and 1-(5'-carboxypentyl)-lepidinium bromide 4 (41 mg, 0.12 mmol) in methanol (5 mL) was added diisopropylethylamine (0.2 mL). The solution was refluxed for 15 min. The solvent was evaporated and the reaction residue triturated with 5% HCl (2 mL). The solid was washed with additional 5% HCl and dried to provide an orange solid (8 mg).

Preparation of nitrothiazole orange succinimidyl ester 10.

To a solution of nitrothiazole orange **9** (8 mg) in dimethylformamide (0.1 mL) and diisopropylethylamine (0.01 mL) was added *O*-(*N*-succinimidyl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (10 mg). The mixture was warmed to 70 °C for 10 min. Reaction progress was monitored by TLC on silica gel using 600:60:16 dichloromethane:methanol:acetic acid as the eluant. To the homogeneous solution was added 5% HCl (1 mL). The precipitate was washed with additional HCl and dried to provide an orange solid (8 mg).

10

EXAMPLE 2
Preparation of Doubly-Labeled Probe for Taqman Assay

Automated synthesis of oligonucleotide probes was performed using an Applied Biosystems Model 394 DNA/RNA synthesizer (The Perkin-Elmer Corporation, PE Applied Biosystems Division (ABD)) according to the general procedures described in the operators manual. The oligonucleotides were synthesized in 0.2 μmol scale using dye-labeled CPG solid supports (Mullah and Andrus, *Tetrahedron Letters*, 38(33): 5751-5754 (1997)), DNA FastPhosphoramidites (User Bulletin number 85, 1994, ABD) and dye-labeled phosphoramidites, FAM and TET (User Bulletin number 78, 1994, ABD). The standard 0.2 μmol synthesis cycle was slightly modified by extending coupling time of FAM amidite by an additional 120 sec (User Bulletin number 78, 1994, ABD). Each probe included a reporter dye attached to a 5'-end of and a quencher dye located at a 3'-end of the probe.

25

After completion of the synthesis, oligonucleotides were autocleaved from the support on the DNA synthesizer by treating with a mixture of MeOH:t-BuNH₂:H₂O (1:1:2) (Woo et al., U.S. Patent No. 5,231,191) using a 1 hr autocleavage procedure ("END CE" procedure) as described in the operators manual for the Applied Biosystems Model 394 DNA/RNA synthesizer. Base protecting groups were removed by heating the mixture at 85 °C for 1 hr or at 65 °C for 3 h.

The crude oligonucleotides were analyzed for purity and integrity by reverse

phase HPLC using the following equipment and conditions: Perkin Elmer Series 200 solvent delivery system equipped with ABI 783A programmable detector; Perkin Elmer ISS200 autosampler; and PE Nelson 900 series data system; RP-18 reverse phase chromatography column (220 X 4.6 mm, ABD); solvent A: 0.1 M triethylammonium acetate; solvent B: CH₃CN; gradient 4-28% B in 35 min; flow rate: 1 mL/min; and detector: 260 nm.

EXAMPLE 3

Taqman Assay for Human Beta Actin Gene

Human genomic DNA was prepared using conventional methods. The composition of the assay reagent was as follows (50 µl total volume):

Component	Conc.	Volume (µl)
dNTPs (dATP, dCTP, dGTP, dUTP)	10 mM ea	4
MgCl ₂	25 mM	7
^a PCR Buffer, 10X	----	5
UNG	1 unit/ml	0.5
Forward PCR Primer	3 µM	5
Reverse PCR Primer	3 µM	5
AmpliTaq™ Gold DNA Polymerase	5 units/ml	0.25
Human Male DNA	10 ng/ml	2
Taqman Probe	2 µM	5
Water	----	16.3

a. 10mM KCl, 100 mM TRIS-HCl, 0.1 M EDTA, 600 nM passive internal standard, pH 8.3.

The reagents were combined in a 96-well microtiter tray and thermally cycled using the following protocol: 50 °C for 2 min; 95 °C for 10 min; 40 cycles of 95 °C for 15 sec followed by 60 °C for 1 min. Fluorescence was monitored during the amplification process using a Applied Biosystems Model 7700 Sequence Detection System (ABD).

The results of a taqman experiment can be analyzed using two parameters; the Rn value and the Ct value. The Rn value is the ratio of the fluorescence of a reporter dye and the fluorescence of a passive reference at the end of a PCR experiment. The Ct value, or threshold cycle number, is the PCR cycle number at which the fluorescence ratio is distinguishable from the background. For a given reporter dye and a fixed concentration of target, both the Rn and Ct values reflect the efficiency of the quencher.


The efficiency of NTB 5 was compared to that of TMR in quenching the reporters FAM and TET. The Rn and Ct values for NTB and TMR were indistinguishable for both reporter dyes. The quencher NTO 9 was used with FAM and found to be equivalent to both NTB and TMR. NTB was paired with the reporter, NED, to provide results that were similar to the other reporters. TMR could not be used as a quencher with the reporter dye NED because the fluorescence emissions of TMR and NED are at the same wavelength.

All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although only a few embodiments have been described in detail above, those having ordinary skill in the molecular biology art will clearly understand that many modifications are possible in the preferred embodiment without departing from the teachings thereof. All such modifications are intended to be encompassed within the following claims.

WE CLAIM:

1. An asymmetric cyanine dye compound having the structure



5

including substituted forms thereof, wherein:

at least one of R₁ and R₂ is linking group; and

X is O, S, or Se;

wherein n ranges from 0 to 2.

10

2. The compound of claim 1 wherein a C-3 substituent is nitro.

3. The compound of claim 1 wherein the linking group is lower alkylamine or lower alkylcarboxy.

15

4. The compound of claim 1 wherein one of R₁ or R₂ is $-(\text{CH}_2)_n\text{N}^+(\text{CH}_3)_3$, where n ranges from 2 to 12, and the other is linking group.

20

5. The compound of claim 3 wherein the lower alkylcarboxy is $-(\text{CH}_2)_n\text{N}^+(\text{CH}_3)_2(\text{CH}_2)_n\text{CO}_2\text{H}$, where n ranges from 2 to 12.

6. The compound of claim 1 wherein X is sulfur.

7. The compound of claim 1 wherein n is 0 or 1.

25

8. The compound of claim 1 having a fused aromatic or substituted aromatic substituent bonded at positions 1 and 2, positions 2 and 3; and/or positions 3 and 4.

30


9. The compound of claim 8 wherein the substituted aromatic includes a nitro substituent.

10. The compound of **claim 1** comprising a bridging group which when taken together with R₂ and the proximate carbon of the methine bridge forms a ring structure
 5 having 5 to 7 members.

11. The compound of **claim 10** wherein the ring structure has 6 members.

12. The compound of **claim 1** having the structure


10



including substituted forms thereof.


13. The compound of **claim 1** having the structure

15




including substituted forms thereof.

14. The compound of **claim 1** having the structure



20 including substituted forms thereof.


15. The compound of **claim 1** having the structure



including substituted forms thereof.

5


16. The compound of **claim 1** having the structure



including substituted forms thereof.

10

17. The compound of **claim 1** having the structure



including substituted forms thereof.

15

18. A reporter-quencher energy-transfer dye pair comprising a reporter dye and a quencher dye, wherein the quencher dye is a cyanine dye quencher of **claim 1**.

19. The reporter-quencher energy-transfer dye pair of **claim 18** wherein the reporter is selected from the group consisting of xanthene, coumarin, napthylamine, cyanine, and bodipy dyes.

20

20. The reporter-quencher energy-transfer dye pair of **claim 19** wherein the reporter is a xanthene dye.

5 21. The reporter-quencher energy-transfer dye pair of **claim 20** wherein the xanthene dye is selected from the group consisting of fluorescein dyes and rhodamine dyes.

10 22. A labeled oligonucleotide comprising:
 an oligonucleotide; and
 a non-fluorescent cyanine dye quencher of **claim 1** covalently attached to the oligonucleotide.

15 23. The labeled oligonucleotide of **claim 22** further including a reporter dye covalently attached to the oligonucleotide.

20 24. The labeled oligonucleotide of **claim 23** wherein the location of the reporter dye and the quencher dye is such that when the labeled oligonucleotide is hybridized to a target nucleic acid sequence the reporter dye is not effectively quenched by the quencher dye, and when the labeled oligonucleotide is not hybridized to a target nucleic acid sequence the reporter dye is effectively quenched by the quencher dye.

25 25. The labeled oligonucleotide of **claim 24** wherein when the reporter dye is effectively quenched its fluorescence is reduced by at least a factor of two as compared to its fluorescence when it is not effectively quenched.

30 26. The labeled oligonucleotide of **claim 25** wherein when the reporter dye is effectively quenched its fluorescence is reduced by at least a factor of six as compared to its fluorescence when it is not effectively quenched.

27. The labeled oligonucleotide of **claim 23** wherein one of the reporter and quencher dyes is attached at a 3'-end of the oligonucleotide and the other is attached at a 5'-end of the oligonucleotide.

28. A method for detecting a target nucleic acid sequence comprising the steps of:
providing a sample nucleic acid including at least one target nucleic acid
5 sequence; and

hybridizing a labeled oligonucleotide probe to the target nucleic acid sequence,
the labeled oligonucleotide probe being labeled with an asymmetric cyanine dye
compound of **claim 1**.

10 29. The method of **claim 28** wherein the labeled oligonucleotide includes a
reporter dye covalently attached to the oligonucleotide.

15 30. The method of **claim 29** wherein the location of the reporter dye and the
quencher dye is such that when the labeled oligonucleotide is hybridized to a target
nucleic acid sequence the reporter dye is not effectively quenched by the quencher dye,
and when the labeled oligonucleotide is not hybridized to a target nucleic acid sequence
the reporter dye is effectively quenched by the quencher dye.

20 31. The method of **claim 30** wherein when the reporter dye is effectively
quenched its fluorescence is reduced by at least a factor of two as compared to its
fluorescence when it is not effectively quenched.


25 32. The labeled oligonucleotide of **claim 31** wherein when the reporter dye is
effectively quenched its fluorescence is reduced by at least a factor of six as compared
to its fluorescence when it is not effectively quenched.

33. The labeled oligonucleotide of **claim 29** wherein one of the reporter and
quencher dyes is attached at a 3'-end of the oligonucleotide and the other is attached at a
5'-end of the oligonucleotide.


30

34. The method of **claim 29** further comprising the step of digesting the
oligonucleotide probe such that one or both of the reporter and quencher dyes is
removed from the oligonucleotide probe.


35. The method of **claim 34** wherein the step of digesting the oligonucleotide probe is effected by a 5'→3' nuclease activity of a polymerase enzyme.



5




20




21


Fig. 1A



22



9



23

Fig. 1B




Fig. 2A




Fig. 2B




Fig. 3A




Fig. 3B




Fig. 3C





Fig. 4A





Fig. 4B




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D






Fig. 5E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/01163

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 6 C09B23/02 C07H21/00 C07H19/04 C12Q1/68		
<p>According to International Patent Classification (IPC) or to both national classification and IPC</p>		
B. FIELDS SEARCHED <p>Minimum documentation searched (classification system followed by classification symbols)</p> <p>IPC 6 C09B C07H</p>		
<p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p>		
<p>Electronic data base consulted during the international search (name of data base and, where practical, search terms used)</p>		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EP 0 710 668 A (BECTON DICKINSON CO) 8 May 1996 see page 4, line 41 - line 51; claims 1,2,5,8; examples 2,3 see page 1, line 10 - line 21 ---</p>	1,3,6,7, 22,28
X	<p>WO 97 45539 A (SVANVIK NICKE ;KUBISTA MIKAEL (SE)) 4 December 1997 see claims 1,27,28; figure 7; example 3 ---</p>	1,3,6,7
X	<p>US 5 321 130 A (YUE STEPHEN T ET AL) 14 June 1994 see claims; example 1; table 1 ---</p>	1,3
X	<p>US 4 883 867 A (LEE LINDA G ET AL) 28 November 1989 see column 1, line 8 - line 16; example 5 ---</p>	1,3,6 -/-
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search		Date of mailing of the international search report
7 May 1999		04/06/1999
Name and mailing address of the ISA		Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016		Ginoux, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/01163

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 714 986 A (TOSOH CORP) 5 June 1996 see claims; examples ---	1,7,22, 28
X	WO 96 04405 A (UNIV CALIFORNIA) 15 February 1996 see compounds 6,10,13,14 see claims ---	1,3,6
X	JP 09 288326 A (FUJI PHOTO FILM CO LTD) 4 November 1997 see compounds 1-17 -& CHEMICAL ABSTRACTS, vol. 128, no. 4, 26 January 1998 Columbus, Ohio, US; abstract no. 41644t, Y. INAGAKI ET AL: "photothermographic material..." page 1162; XP002102134 see abstract ---	1,3,6,8
A	WO 96 15270 A (PERKIN ELMER CORP) 23 May 1996 see page 11, line 5 - line 10 see page 18, line 16 - line 27; claims ----	1-35

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/01163

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0710668	A	08-05-1996	US 5597696 A		28-01-1997
			CA 2152446 A		19-01-1996
			JP 2809340 B		08-10-1998
			JP 8059689 A		05-03-1996
WO 9745539	A	04-12-1997	SE 506700 C		02-02-1998
			AU 3112997 A		05-01-1998
			SE 9602183 A		01-12-1997
US 5321130	A	14-06-1994	NONE		
US 4883867	A	28-11-1989	US 4957870 A		18-09-1990
			EP 0226272 A		24-06-1987
			JP 1594638 C		27-12-1990
			JP 2019428 B		01-05-1990
			JP 62112062 A		23-05-1987
EP 0714986	A	05-06-1996	JP 8211050 A		20-08-1996
			US 5814447 A		29-09-1998
WO 9604405	A	15-02-1996	US 5565554 A		15-10-1996
			US 5760201 A		02-06-1998
JP 09288326	A	04-11-1997	NONE		
WO 9615270	A	23-05-1996	US 5538848 A		23-07-1996
			AU 695561 B		13-08-1998
			AU 4283696 A		06-06-1996
			CA 2201756 A		23-05-1996
			EP 0792374 A		03-09-1997
			JP 10510982 T		27-10-1998
			US 5876930 A		02-03-1999
			US 5723591 A		03-03-1998